NCT00315939

Brief Summary

The purpose of this study is to test two newly developed computer programs, Integrated Biobehavioral Monitoring and Feedback (IBMF) IBMF-1 and IBMF-2. The computer programs are considered experimental. Both computer programs are being tested to see if they are useful in helping people with type 1 diabetes avoid low blood sugar episodes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2006

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2006

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

April 18, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 19, 2006

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2009

Completed
4.8 years until next milestone

Results Posted

Study results publicly available

September 9, 2014

Completed
Last Updated

September 18, 2014

Status Verified

August 1, 2014

Enrollment Period

3.9 years

First QC Date

April 18, 2006

Results QC Date

August 8, 2014

Last Update Submit

September 9, 2014

Conditions

Keywords

Diabeteshypoglycemic episodes

Outcome Measures

Primary Outcomes (2)

  • Hemoglobin A1c

    1 year (each level lasted 3 months)

  • Frequency of Severe Hypoglycemia

    Severe hypoglycemia (SH) was defined to subjects as "blood glucose so low that you could not treat yourself because you were stuporous or unconscious."

    1 year (each level lasted 3 months)

Study Arms (2)

Group A Order: SMBG, IBMF-1, IBMF-2

EXPERIMENTAL

Group A performed routine self-monitored blood glucose (SMBG) alone (level 1), followed sequentially by Integrated Biobehavioral Monitoring \& Feedback - 1 (IBMF-1) level 2 and Integrated Biobehavioral Monitoring \& Feedback - 2 (IBMF-2) level 3. Each level continued for 3 months.

Device: Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1)Device: Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)

Group B Order: IBMF-1, IBMF-2, SMBG

EXPERIMENTAL

Group B began with Integrated Biobehavioral Monitoring \& Feedback - 1 (IBMF-1) level 2, followed by level 3, Integrated Biobehavioral Monitoring \& Feedback - 2 (IBMF-2) and then level 1 (SMBG only). Each level continued for 3 months.

Device: Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1)Device: Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)

Interventions

Integrated Biobehavioral Monitoring \& Feedback-1 (IBMF-1): a hand-held computer (HHC) was given to the subjects, programmed to estimate HbA1c, risk for hypoglycemia (Low BG Index), and glucose variability (Average Daily Risk Range) using previously published algorithms. The subjects were asked to carry the HHC and enter all their self-monitored blood glucose (SMBG) readings. The estimates of HbA1c were updated weekly, and the estimates of risk for hypoglycemia and glucose variability were updated at each SMBG entry. Detailed instructions were provided on the meaning of these different types of glucose feedback; the study staff was available to answer any questions.

Group A Order: SMBG, IBMF-1, IBMF-2Group B Order: IBMF-1, IBMF-2, SMBG

Integrated Biobehavioral Monitoring \& Feedback-2 (IMBF-2) retains IMBF-1, but the HHC asked subjects to provide symptom ratings when blood glucose (BG) was low and at an equal number of matching euglycemic readings. From these data, the HHC estimated a set of potentially significant symptoms of hypoglycemia for each individual, using an iterative algorithm following a previously published symptom significance estimation procedure. The patient manual for the HHC program is provided in supplementary data of published manuscript.

Group A Order: SMBG, IBMF-1, IBMF-2Group B Order: IBMF-1, IBMF-2, SMBG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age or older
  • Have type 1 diabetes as defined by the American Diabetes Association or by the judgment of the physician
  • Willing to participate for up to one year
  • Perform routine blood glucose checks 3-4 times a day
  • Complete monthly diaries of the occurrence of severe and moderate hypoglycemic episodes
  • Have 6 hemoglobin A1c (HgbA1c) drawn
  • Have a mixed meal tolerance test to assess for residual pancreatic insulin secretion

You may not qualify if:

  • Age \< 18 years
  • Currently abusing alcohol or drugs
  • Severe depression or psychosis
  • Significant mental impairment
  • Inability to use a glucometer and a hand held computer
  • Pregnant or desire to achieve pregnancy within the following year (females)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Virginia

Charlottesville, Virginia, 22903, United States

Location

Related Publications (1)

  • Kovatchev BP, Mendosa P, Anderson S, Hawley JS, Ritterband LM, Gonder-Frederick L. Effect of automated bio-behavioral feedback on the control of type 1 diabetes. Diabetes Care. 2011 Feb;34(2):302-7. doi: 10.2337/dc10-1366. Epub 2011 Jan 7.

    PMID: 21216860BACKGROUND

MeSH Terms

Conditions

Diabetes Mellitus, Type 1Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Results Point of Contact

Title
Boris Kovatchev, PhD
Organization
University of Virginia

Study Officials

  • Boris Kovatchev, Ph.D.

    University of Virginia, Department of Psychiatric Medicine, Behavioral Medicine Research

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 18, 2006

First Posted

April 19, 2006

Study Start

January 1, 2006

Primary Completion

December 1, 2009

Study Completion

December 1, 2009

Last Updated

September 18, 2014

Results First Posted

September 9, 2014

Record last verified: 2014-08

Locations